当前位置: 首页 >> 检索结果
501. Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry.
作者: Khodr Tello.;Athiththan Yogeswaran.;Raphael W Majeed.;David G Kiely.;Allan Lawrie.;Evan Brittain.;Jeffrey S Annis.;Horst Olschewski.;Gabor Kovacs.;Paul M Hassoun.;Aparna Balasubramanian.;Ziad Konswa.;Andrew J Sweatt.;Roham T Zamanian.;Martin R Wilkins.;Luke Howard.;Alexandra Arvanitaki.;George Giannakoulas.;Hector R Cajigas.;Robert Frantz.;Paul G Williams.;Marlize Frauendorf.;Kurt Marquardt.;Tobiah Antoine.;Meike Fuenderich.;Manuel Richter.;Friedrich Grimminger.;Hossein-Ardeschir Ghofrani.;Jochen Wilhelm.;Werner Seeger.; .
来源: Chest. 2025年167卷1期224-240页
Patients with COPD frequently demonstrate pulmonary hypertension (PH). Severe PH in patients with COPD, identified by pulmonary vascular resistance (PVR) of > 5 Wood units (WU), is closely linked to impaired transplant-free survival. The impact of PH-targeting pharmacotherapy in this context remains unclear.
502. Advancing Point-of-Care Testing by Application of Machine Learning Techniques and Artificial Intelligence.
作者: Craig M Lilly.;Apurv V Soni.;Denise Dunlap.;Nathaniel Hafer.;Mary Ann Picard.;Bryan Buchholz.;David D McManus.
来源: Chest. 2025年167卷1期152-159页
The promise of artificial intelligence has generated enthusiasm among patients, health care professionals, and technology developers who seek to leverage its potential to enhance the diagnosis and management of an increasing number of chronic and acute conditions. Point-of-care testing increases access to care because it enables care outside of traditional medical settings. Collaboration among developers, clinicians, and end users is an effective best practice for solving clinical problems. A common set of clearly defined terms that are easily understood by research teams is a valuable tool that fosters these collaborations.
503. Incidence, Risk Factors, and Long-Term Outcomes for Extubation Failure in ICU in Patients With Obesity: A Retrospective Analysis of a Multicenter Prospective Observational Study.
作者: Audrey De Jong.;Mathieu Capdevila.;Yassir Aarab.;Matthieu Cros.;Joris Pensier.;Ines Lakbar.;Clément Monet.;Hervé Quintard.;Raphael Cinotti.;Karim Asehnoune.;Jean-Michel Arnal.;Christophe Guitton.;Catherine Paugam-Burtz.;Paer Abback.;Armand Mekontso-Dessap.;Karim Lakhal.;Sigismond Lasocki.;Gaetan Plantefeve.;Bernard Claud.;Julien Pottecher.;Philippe Corne.;Carole Ichai.;Nicolas Molinari.;Gerald Chanques.;Laurent Papazian.;Elie Azoulay.;Samir Jaber.; .
来源: Chest. 2025年167卷1期139-151页
To our knowledge, no large observational study has compared the incidence and risk factors for extubation failure within 48 h and during ICU stay in the same cohort of unselected critically ill patients with and without obesity.
504. Association of Cardiopulmonary Hemodynamics and Outcomes in Pulmonary Hypertension Following Kidney Transplantation: A Multicenter Retrospective Cohort Study.
作者: Arun Jose.;Sathish S Kumar.;Leonid Gorelik.;Samuel H Friedman.;Antolin S Flores.;Denise Sese.;Michael Vinzani.;Nicholas J Douville.;Akshar Patel.;Rahul G Argula.;Courtney Jones.;Nicole M Bhave.;Jean M Elwing.
来源: Chest. 2024年166卷6期1499-1510页
Pulmonary hypertension (PH) frequently complicates the evaluation of kidney transplantation (KT) candidates, and is associated with increased adverse outcomes (mortality, delayed graft function [DGF], and major adverse cardiovascular event) following KT.
505. Ethnic Variation in Asthma Prevalence Across Childhood in the Asian American and Pacific Islander Population.
作者: Julia G Costantini.;Joan C Lo.;Jimmy Ko.;Malini Chandra.;Polly Huang.;Jeanne A Darbinian.;Anna Chen Arroyo.
来源: Chest. 2025年167卷2期343-347页 506. Inpatient Complication Rates of Bronchoscopic Lung Volume Reduction in the United States.
作者: Francisco F Costa Filho.;Jonh D Buckley.;Alan Furlan.;Samantha Campbell.;Kirsten Hickok.;Philip J Kroth.
来源: Chest. 2025年167卷2期436-443页
Early randomized controlled trials (RCTs) of bronchoscopic lung volume reduction (BLVR) have shown clinically meaningful benefits in lung function, dyspnea, and quality of life in patients with severe emphysema. Safety outcome data obtained after BLVR in the United States are scarce outside the RCTs.
507. BAL Fluid Cellular Analysis and Radiologic Patterns in Patients With Fibrotic Interstitial Lung Disease.
作者: Amanda Grant-Orser.;Michael Asmussen.;Daniel-Costin Marinescu.;Cameron J Hague.;Nestor L Muller.;Darra T Murphy.;Andrew Churg.;Joanne L Wright.;Amna Al-Arnawoot.;Ana-Maria Bilawich.;Patrick Bourgouin.;Gerard Cox.;Celine Durand.;Tracy Elliot.;Jennifer Ellis.;Jolene H Fisher.;Derek Fladeland.;Gillian C Goobie.;Zachary Guenther.;Ehsan Haider.;Nathan Hambly.;James Huynh.;Geoffrey Karjala.;Nasreen Khalil.;Martin Kolb.;Jonathon Leipsic.;Stacey Lok.;Sarah MacIsaac.;Micheal McInnis.;Helene Manganas.;Veronica Marcoux.;John Mayo.;Julie Morisset.;Ciaran Scallan.;Tony Sedlic.;Shane Shapera.;Kelly Sun.;Victoria Tan.;Alyson W Wong.;Boyang Zheng.;Christopher J Ryerson.;Kerri A Johannson.
来源: Chest. 2025年167卷1期172-182页
BAL cellular analysis is often recommended during the initial diagnostic evaluation of fibrotic interstitial lung disease (ILD). Despite recommendation for its use, between-center heterogeneity exists and supportive data concerning the clinical utility and correlation of BAL findings with radiologic features or patterns remain sparse.
508. The Responsiveness of Exercise Tests in COPD: A Randomized Controlled Trial.
作者: Theresa C Harvey-Dunstan.;Molly M Baldwin.;Ruth Tal-Singer.;Matthew Allinder.;Michael I Polkey.;Alan Hamilton.;Matthew Richardson.;Sarah A Edwards.;Michael C Steiner.;Mike D Morgan.;Sally J Singh.; .
来源: Chest. 2025年167卷1期98-111页
COPD is characterized by reduced exercise tolerance, and improving physical performance is an important therapeutic goal. A variety of exercise tests are commonly used to assess exercise tolerance, including laboratory and field-based tests. The responsiveness of these various tests to common COPD interventions is yet to be compared, but the results may inform test selection in clinical and research settings.
509. Diffuse Cystic Lung Disease: A Clinical Guide to Recognition and Management.
作者: Alessandro N Franciosi.;Nishant Gupta.;David J Murphy.;Kathryn A Wikenheiser-Brokamp.;Cormac McCarthy.
来源: Chest. 2025年167卷2期529-547页
Diffuse cystic lung diseases (DCLDs) represent a group of pathophysiologically heterogeneous entities that share a common radiologic phenotype of multiple thin-walled pulmonary cysts. DCLDs differ from the typical fibroinflammatory interstitial lung diseases in their epidemiology, clinical presentation, molecular pathogenesis, and therapeutic approaches, making them worthy of a distinct classification. The importance of timely and accurate identification of DCLDs is heightened by the impact on patient management including recent discoveries of targeted therapeutic approaches for some disorders.
510. Nocturnal Cardiac Arrhythmias in Heart Failure With Obstructive and Central Sleep Apnea.
作者: Christian M Horvath.;Christoph Fisser.;John S Floras.;Samuel Sossalla.;Stella Wang.;George Tomlinson.;Fiona Rankin.;Shoichiro Yatsu.;Clodagh M Ryan.;T Douglas Bradley.;Michael Arzt.; .
来源: Chest. 2024年166卷6期1546-1556页
Both obstructive and central sleep apnea (CSA) may contribute to nocturnal cardiac arrhythmias (NCAs). Data are scarce regarding the prevalence of clinically important nocturnal atrial and ventricular arrythmias in patients with heart failure with reduced ejection fraction (HFrEF) and OSA or CSA.
511. Extracellular Vesicle-Encapsulated microRNAs and Respiratory Health Among American Indian Participants in the Strong Heart Study.
作者: Christina M Eckhardt.;Haotian Wu.;Gabriela Jackson.;Marisa H Sobel.;Tessa Bloomquist.;Adnan Divjan.;Hadler da Silva.;Lyle G Best.;Shelley Cole.;Jason Umans.;Ying Zhang.;Peter de Hoff.;Louise C Laurent.;Matthew S Perzanowski.;Ke Cheng.;Andrea A Baccarelli.;Tiffany R Sanchez.
来源: Chest. 2025年167卷1期87-97页
American Indian populations have experienced marked disparities in respiratory disease burden. Extracellular vesicle-encapsulated microRNAs (EV-miRNAs) are a novel class of biomarkers that may improve recognition of lung damage in indigenous populations in the United States.
512. Quantitative Imaging Methods in Combined Pulmonary Fibrosis and Emphysema.
作者: Jennifer M Wang.;Tetsuro Araki.;Vincent Cottin.;MeiLan K Han.;Justin M Oldham.
来源: Chest. 2024年166卷6期1463-1472页
Combined pulmonary fibrosis and emphysema (CPFE) is an underdiagnosed syndrome in which individuals have variable degrees of pulmonary fibrosis and emphysema. Patients with CPFE have high morbidity, including poor exercise tolerance and increased development of comorbidities. CPFE mortality also seems to outpace that of lone emphysema and pulmonary fibrosis. A major limitation to rigorous, large-scale studies of CPFE has been the lack of a precise definition for this syndrome. A 2022 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association research statement called attention to fundamental gaps in our understanding of CPFE and highlighted the potential use of quantitative imaging techniques to better define CPFE.
513. Evaluating US Multiple Listing Practices in Lung Transplantation: Unveiling Hidden Disparities.
作者: Adora N Moneme.;Mallory Hunt.;Jacqueline Friskey.;Madeline McCurry.;Dun Jin.;Joshua M Diamond.;Michaela R Anderson.;Emily S Clausen.;Aya Saleh.;Allie Raevsky.;Jason D Christie.;Douglas Schaubel.;Jesse Hsu.;A Russell Localio.;Robert Gallop.;Edward Cantu.
来源: Chest. 2024年166卷6期1442-1454页
Multiple listing (ML) is a practice used to increase the potential for transplant but is controversial due to concerns that it disproportionately benefits patients with greater access to health care resources.
514. Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models.
作者: Megan Griffiths.;Catherine E Simpson.;Jun Yang.;Dhananjay Vaidya.;Melanie K Nies.;Stephanie Brandal.;Rachel Damico.;Paul Hassoun.;Dunbar D Ivy.;Eric D Austin.;Michael W Pauciulo.;Katie A Lutz.;Lisa J Martin.;Erika B Rosenzweig.;Raymond L Benza.;William C Nichols.;Cedric Manlhiot.;Allen D Everett.
来源: Chest. 2024年166卷6期1511-1531页
Risk assessment in pulmonary arterial hypertension (PAH) is fundamental to guiding treatment and improved outcomes. Clinical models are excellent at identifying high-risk patients, but leave uncertainty amongst moderate-risk patients.
515. Biomarker Testing for Guiding Precision Medicine for Patients With Non-Small Cell Lung Cancer.
作者: Adam H Fox.;Mariam Alexander.;Jessica A Forcucci.;Gerard A Silvestri.
来源: Chest. 2024年166卷5期1239-1249页
The initial management of patients with lung cancer is growing more complex in the context of an expanding number of precision medicine treatments. These challenges are accompanied by opportunities to deliver more efficacious and less toxic treatments to patients. Indications for these treatments are also expanding, and patients with lung cancer across multiple stages now require biomarker testing. Given their role in the initial management of patients being diagnosed with lung cancer, pulmonologists must have fundamental knowledge regarding the importance, indications, and implications of biomarker testing across the spectrum of histology and stage. The purpose of this review is to provide fundamental knowledge regarding biomarker testing, its incorporation into the initial diagnostic and staging evaluation, and guidance for working within a multidisciplinary team to achieve timely and comprehensive biomarker testing to direct the use of precision medicine treatments.
516. Longitudinal Changes in Maximal Forced Inspiratory Flow and Clinical Outcomes in Patients With COPD.
作者: Dong Hyun Kim.;Eun-Tae Jeon.;Hyo Jin Lee.;Heemoon Park.;Jung-Kyu Lee.;Eun Young Heo.;Deog Kyeom Kim.;Hyun Woo Lee.
来源: Chest. 2025年167卷1期76-86页
COPD primarily impairs expiratory flow due to progressive airflow obstruction and reduced lung elasticity. Increasing evidence underlines the importance of inspiratory flow as a biomarker for selecting inhaler devices and providing ancillary aerodynamic information.
517. Occupational Exposure to Charcoal Smoke and Dust, a Major Risk Factor for COPD: A Multiregional Cross-Sectional Study in the Democratic Republic of Congo.
作者: Pierre Olenga Vuvu Lofuta.;Malgorzata Klass.;Nathalie Pauwen.;Augustin Mboko Kipula.;Philippe van de Borne.;Alain Van Muylem.;Silvia Perez-Bogerd.;Gaël Deboeck.
来源: Chest. 2024年166卷6期1334-1346页
Occupational exposure to charcoal smoke and dust is a threat to workers' respiratory systems.
518. Identifying Risk of Postoperative Cardiorespiratory Complications in OSA.
作者: Maree Azzopardi.;Richard Parsons.;Gemma Cadby.;Stuart King.;Nigel McArdle.;Bhajan Singh.;David R Hillman.
来源: Chest. 2024年166卷5期1197-1208页
Patients with OSA are at increased risk of postoperative cardiorespiratory complications and death. Attempts to stratify this risk have been inadequate, and predictors from large, well-characterized cohort studies are needed.
519. Decídetexto: Mobile Cessation Support for Latino Adults Who Smoke: A Randomized Clinical Trial.
作者: Francisco Cartujano-Barrera.;Lisa Sanderson Cox.;Delwyn Catley.;Xueya Cai.;Francisco J Diaz.;Evelyn Arana-Chicas.;Arlette Chávez-Iñiguez.;Chinwe Ogedegbe.;Kristi D Graves.;M Patricia Rivera.;Arturo Ponce.;Edward F Ellerbeck.;Ana Paula Cupertino.
来源: Chest. 2025年167卷2期619-629页
Latino adults experience multiple barriers to health care access and treatment that result in tobacco-related disparities. Mobile interventions have the potential to deliver smoking cessation treatment among Latino adults, who show the highest use rates of mobile technologies.
520. Longitudinal Assessment of Communication With Patient-Reported Outcomes During Lung Cancer Screening.
作者: Christopher G Slatore.;Sara E Golden.;Liana Schweiger.;Ian Ilea.;Donald R Sullivan.;Sean P M Rice.;Renda Soylemez Wiener.;Santanu Datta.;James M Davis.;Anne C Melzer.
来源: Chest. 2025年167卷3期876-891页
Many organizations recommend clinicians use structured communication processes, referred to as shared decision-making, to improve patient-reported outcomes for patients considering lung cancer screening (LCS).
|